Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK sends first of 100 million promised vaccine doses to poorer nations

Wed, 28th Jul 2021 16:35

(Alliance News) - The first batch of excess coronavirus vaccines from Britain will be shipped off to "vulnerable" nations and Commonwealth allies this week, the UK Foreign Secretary has announced.

Leaders of the major industrialised nations at the G7 summit in Cornwall pledged more than one billion doses of Covid-19 vaccine – 870 million jabs shared directly and the rest through funding to the Covax initiative – to poorer countries.

Prime Minister Boris Johnson confirmed the UK's contribution to the one billion dose pledge is another 100 million vaccines from now to next June, with Dominic Raab announcing on Wednesday that the first shipment of nine million spare Oxford-AstraZeneca PLC will be made this week.

And in a message to western countries who have unused stockpiles of AstraZeneca jabs, Raab stressed that bodies ranging from the World Health Organisation to the European Medicines Agency had approved the British-designed vaccine as safe, arguing it was "crucially important" for all nations to vaccinate their populations.

It comes as parts of Australia have been forced to go back into lockdown despite the UK ally having three million unboxed doses of the AstraZeneca inoculation stored, according to reports.

Fears about the Oxford jab's side effects, including an increased risk of blood clots, have seen it shunned in some wealthy countries.

The Foreign Secretary visited an AstraZeneca manufacturing site in Oxford on Wednesday to announce that the first despatch of excess UK doses will be making their way to poorer nations this week – with five million to be distributed via the WHO's Covax scheme and another four million bilaterally.

Speaking to the PA news agency after the visit, the Cabinet minister said: "We succeeded in double-vaccinating 70% of the adult population, the UK economy is bouncing back but we know we're not going to be safe in the UK until everyone is safe.

"That is why we have been leading the (international) vaccine rollout to give enough doses to get the world vaccinated by the middle of next year, rather than the current trajectory, which is the end of 2024."

Raab said the UK was delivering on its G7 pledge of sending 100 million surplus vaccines to the "poorest and most vulnerable countries around the world" before the middle of 2022.

"The first nine million doses will be going on Friday to countries from vulnerable countries in the Indo-Pacific, such as Laos, Cambodia, key partners like Indonesia, right the way through the Commonwealth countries from Kenya to Jamaica," the Cabinet minister added.

"I think what it shows, as well as the domestic rollout and the importance of coming out of the lockdowns in the UK, is that global Britain is also a lifesaving force for good in the world."

Indonesia will receive 600,000 doses of those being handed out bilaterally, 300,000 will be sent to Jamaica and 817,000 are to be transported to Kenya, among other countries, the Foreign Office said.

Raab, who is also First Secretary of State, joined the prime minister and fellow Cabinet colleague Therese Coffey in refusing to repeat Michael Gove's assertion that it was "selfish" to refuse a vaccine.

The Chancellor of the Duchy of Lancaster's comment comes as the government prepares to make being double-jabbed a condition of entry to nightclubs in September in a bid to increase the number of young people coming forward for inoculation.

Asked what he made of Gove's remark, Raab told PA: "Look, I think people should get vaccinated for their own self-interest because it is far safer to do so, and I would encourage everyone to do so."

Professor Sir John Bell said the UK's decision to send unneeded Covid-19 vaccines to developing nations was "long overdue" and would help guard against new variants of the virus forming.

The Regius Professor of Medicine at Oxford University told BBC Radio 4's World At One programme: "I think it is a bit self-indulgent, to be honest, of western countries fretting about these kinds of issues (what rights to afford the fully vaccinated) when the vast majority of the globe remains completely unvaccinated, with massive levels of viral replication sweeping through the population.

"If you want variants, you've got the perfect storm for that, and it is not in Watford – it is in Zimbabwe and Rwanda and South Africa."

By Patrick Daly, PA Political Correspondent

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.